NYSE:USNA - USANA Health Sciences Stock Price, Price Target & More

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences declared that its board has approved a stock repurchase plan on Wednesday, July 26th 2017, which allows the company to repurchase $64,600,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 46% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) released its earnings results on Tuesday, April, 24th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.05 by $0.14. The company had revenue of $292 million for the quarter, compared to the consensus estimate of $268.93 million. USANA Health Sciences had a return on equity of 27.92% and a net margin of 6.47%. The firm's quarterly revenue was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.91 EPS. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $4.25-4.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.37. The company issued revenue guidance of $1.13-1.17 billion, compared to the consensus revenue estimate of $1.12 billion.

2 analysts have issued 1-year price objectives for USANA Health Sciences' shares. Their forecasts range from $95.00 to $95.00. On average, they anticipate USANA Health Sciences' stock price to reach $95.00 in the next year. This suggests that the stock has a possible downside of 13.4%. View Analyst Ratings for USANA Health Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to USANA Health Sciences include Stada Arzneimittel (STDAF), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG) and Entia Biosciences (ERGO).

News stories about USNA stock have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. USANA Health Sciences earned a media sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the company an impact score of 45.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

USANA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include WENTZ MYRON W (43.80%), Hays Advisory LLC (0.11%), Bank of Montreal Can (0.02%), Hartford Investment Management Co. (0.01%), Campbell & CO Investment Adviser LLC (0.01%) and Creative Planning (0.01%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Deborah Woo, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Hays Advisory LLC and Creative Planning. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, David Mulham Mulham, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Hartford Investment Management Co., Campbell & CO Investment Adviser LLC, RNC Capital Management LLC and Amalgamated Bank. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $109.75.

USANA Health Sciences has a market capitalization of $2.68 billion and generates $1.05 billion in revenue each year. The company earns $62.53 million in net income (profit) each year or $4.06 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]